Rep. Duckworth Questions Mylan CEO on EpiPen Sales to Schools

Mylan CEO Heather Bresch responded to questions Wednesday from the House Oversight Committee regarding costs of the EpiPen and the price and conditions for the sale of the item to schools. The company raised the list price of the allergy medication 548% over the last nine years, reigniting public outrage over drug prices. Subscribe to the WSJ channel here: More from the Wall Street Journal: Visit : Follow WSJ on Facebook: Follow WSJ on Google : wsj/posts Follow WSJ on Twitter: Follow WSJ on Instagram: Follow WSJ on Pinterest: Don’t miss a WSJ video, subscribe here: More from the Wall Street Journal: Visit : Visit the WSJ Video Center: On Facebook: O